Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revvity (GB:0KHE)
LSE:0KHE
Revvity (0KHE) Share Price & Analysis
0 Followers
0KHE Stock Chart & Stats
Day’s Range$101.05 - $102.95
52-Week Range― - ―
Previous Close$102.21
Volume11.00
Average Volume (3M)N/A
Market Cap
$12.78B
Enterprise Value$15.21B
Total Cash (Recent Filing)$1.60B
Total Debt (Recent Filing)$4.03B
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Apr 29, 2024EPS Estimate
$0.94Last Dividend Ex-Date
Apr 18, 2024Dividend Yield0.27%
Share Statistics
EPS (TTM)N/A
Shares Outstanding123,529,821
10 Day Avg. Volume123
30 Day Avg. Volume56
Standard Deviation0.08
R-Squared0.20
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-7.54
Price to Sales (P/S)6.88
Price to Cash Flow (P/CF)16.10
P/FCF Ratio14.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda47.43
Forecast
1Y Price Target
$117.11Price Target Upside15.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Revvity News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceRVTY's initial 2024 revenue guidance exceeded market expectations, signaling a promising return to organic revenue growth.
Operational EfficiencyManagement's effective cost control measures have significantly reduced back-office and fixed costs, potentially leading to improved financial performance.
Revenue GrowthThe Immunodiagnostics sector in China is projected to grow, with new screening assays anticipated to mitigate the impact of declining birth rates on RVTY's revenue.
Bears Say
Earnings GuidanceGuidance implies a somewhat lower 1Q starting point than Street modeled.
Financial PerformanceCore growth declined -3% and decelerated on a 2-year stack.
Sector ChallengesActivity in Biopharma is expected to stay subdued through at least the first half of the next year, as customers continue to deal with a muted funding environment, tight budgets, and the hangover from COVID-era overspending.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.93% Insiders
37.48% Mutual Funds
21.54% Other Institutional Investors
39.05% Public Companies and
Individual Investors
0KHE FAQ
What was Revvity’s price range in the past 12 months?
Currently, no data Available
What is Revvity’s market cap?
Currently, no data Available
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Apr 29, 2024 which is in 2 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Feb 01, 2024. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.165 by $0.085.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.27%. See more information on Revvity dividends here
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is $0.94.
How many shares outstanding does Revvity have?
Currently, no data Available
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $1.25 in its last earnings report, beating expectations of $1.165. Following the earnings report the stock price went down -1.041%.
Which hedge fund is a major shareholder of Revvity?
Among the largest hedge funds holding Revvity’s share is Independent Franchise Partners Llp. It holds Revvity’s shares valued at 211M.
---
Revvity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$117.11 (15.44% Upside)
$117.11 (15.44% Upside)
Blogger Sentiment
Bullish
GB:0KHE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.73%
12-Months-Change
Fundamentals
Return on Equity
2.35%
Trailing 12-Months
Asset Growth
-4.00%
Trailing 12-Months
Company Description
Revvity
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.
---
0KHE Company Deck
---
0KHE Earnings Call
Q4 2024
0:00 / 0:00
---
0KHE Revenue Breakdown
53.02% Diagnostics
46.98% Life sciences
---
0KHE Stock 12 Months Forecast
Average Price Target
$117.11
▲(15.44% Upside)
Technical Analysis
Best Analysts Covering 0KHE
1 Year
1 Year Success Rate
16/29 ratings generated profit
1 Year Average Return
+8.07%
reiterated a buy rating 6 days ago
Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +8.07% per trade.
---